Antipsychotic medications reduce relapse risk about 60% compared to placebo, according to the results of a Cochrane meta-analysis (Leucht et al. Lancet 2012;379:2063-2071. The analysis included 65 trials (n=6,493).
Latest News
RIS: what are the risk factors for CIS/MS?
February 13, 2013There has been little information on the natural history of radiologically isolated syndrome (RIS) since it was first described in 2009 (Okuda et al. Neurology 2009;72:800-805).
The Year in (P)review – MS 2013 – Is the Injectable Era (almost) Over?
January 31, 2013The year 2013 will likely see the launch of two new oral agents for the treatment of multiple sclerosis – teriflunomide (already available in the U.S. as Aubagio), and BG-12. They will join fingolimod (Gilenya), the first of the oral MS drugs (following the withdrawal of cladribine). Fingolimod is indicated as a first-line (in the U.S.) or second-line (in Canada) treatment for relapsing forms of MS (RRMS).
Teriflunomide and BG-12 are also expected to be accorded first- or second-line status following their review by regulators.
Generation ABCR
Oral vs. injectable
Patient preference and practice
Side effect burden
Next generation
End of an era?
Comment by Dr. Grand’Maison
Preventing relapses in schizophrenia: meta-analysis
January 9, 2013Antipsychotic medications reduce relapse risk about 60% compared to placebo, according to the results of a Cochrane meta-analysis (Leucht et al. Lancet 2012;379:2063-2071. The analysis included 65 trials (n=6,493).